Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Tobramycin for Bacterial Conjunctivitis (C-01-401-004)

Inclusion Criteria: * Male or female subject, of any race, who is at least 1 year of age. * Subjects must have a clinical diagnosis of acute bacterial conjunctivitis and exhibit mucopurulent or purulent conjunctival discharge (crusty or sticky eyelids, globular and yellow discharge) and redness in at least one eye. * The symptoms of bacterial conjunctivitis must be present for 3 days (approximately 72 hours) or less. * Must be willing to discontinue contact lens wear for the duration of the study. Exclusion Criteria: * Any uncontrolled systemic disease or debilitating disease. * Use of topical ophthalmic solutions including tear substitutes within 2 hours before and during the study. * Use of any topical ophthalmic anti-inflammatory agents within 48 hours before and during study. * Any active upper respiratory tract infection. * Pregnant or nursing females. * Use of any antibiotic (topical or systemic) within 72 hours of enrollment.